loader image
Monday, November 4, 2024
89.3 F
McAllen
We Welcome your Press Release
- Advertisement -

Cornyn Compares Prescription Drug Patent Strategies to Money Laundering

Translate to Spanish or other 102 languages!

James Stansel, Senator John Cornyn, and Michael Carrier
James Stansel, Senator John Cornyn, and Michael Carrier

Mega Doctor News

- Advertisement -

Washington – During a Senate Judiciary Committee hearing on drug pricing, U.S. Senator John Cornyn (R-TX) questioned James Stansel, General Counsel for Pharmaceutical Research and Manufacturers of America, and Michael Carrier, Professor of Law at Rutgers Law School, on pharmaceutical manufacturers’ utilization of the patent system to prevent competition on certain prescription drugs. Excerpts of Sen. Cornyn’s line of questioning are below.

Senator John Cornyn: “Just like a financial transaction could be legal in and of itself under certain circumstances, the federal government has defined as money laundering structuring arrangements that are designed to accomplish a certain result… assuming the patent itself was legal, my question is, could they be structured in such a way as to result in an anti-competitive effect?”

James Stansel: “Well, I do think that where there’s concern, you know, product hopping has been mentioned, if there’s a specific conduct in the marketplace that a company is engaged in…”

- Advertisement -

Sen. Cornyn: “Professor Carrier, what if we gave the FTC the authority to look at that sort of patent thickets and decide whether there was a noncompetitive effect and provide an equitable remedy?”

Michael Carrier: “I think that would make perfect sense and that would deal with the problem here… This is an abuse of the system and giving the FTC power to deal with it will be a great development.”

Senator John Cornyn, a Republican from Texas, is a member of the Senate Finance, Intelligence, and Judiciary Committees.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

FDA Approves First CRISPR Gene Therapy to Treat Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

DHR Health Brownsville Leads the Way in Minimally Invasive Robotic Surgery

DHR Health stands at the forefront of minimally invasive robotic surgery in South Texas, exemplified by its Institute of Robotic Surgery, which successfully completes over 1,000 robotic cases annually. With the recent inauguration of DHR Health Brownsville, this advanced expertise in Minimally Invasive Surgical procedures is extending its reach to the lower Rio Grande Valley. In a groundbreaking milestone last month, Dr. Rene Luna conducted DHR Health Brownsville's inaugural Robotic Surgery.

Pieology Donates 100 Gallons Of Hand Sanitizer To DHR Health

Agustin Guzman and Juan Garza of Pieology said they receive so much support from their communities and businesses, including DHR Health employees who love their pizza, and wanted to give back in a way that offers the hospital system some additional resources to help keep staff and patients protected from the spread of COVID-19 or any other viruses.
- Advertisement -
×